Mechanisms and treatments of lymphedema

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Lymphedema refers to the interstitial edema caused by obstruction of lymph drainage. The clinical symptoms of lymphedema include local swelling and pain, thickened and rough skin, limited walking and repeated infection. Genetic mutation, fat deposition, aging and lymphatic filariasis may contribute to the pathogenesis of lymphedema. CD4 + T cells also promote the development of lymphedema. Cell junctions between adjacent lymphatic endothelial cells (LECs) are crucial to maintain the integrity of lymphatic vessels, and damage of these junctions increases the vessel permeability and induces lymphedema. VEGF-C-VEGFR3 signaling is a key regulator of lymphangiogenesis, whereas inflammatory mediators modulate lymphatic repair in a context-dependent manner. Current management includes conservative therapy and selected surgical approaches, while lymphangiogenic, pharmacologic, and cell-based treatments remain largely investigational. In this review, we summarize pathogenic factors associated with lymphedema, mechanisms regulating lymphatic endothelial permeability and lymphangiogenesis, and emerging therapeutic strategies.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.